|
AstraZeneca PLC on Monday reported positive phase three results for its monoclonal antibody, Tozorakimab, meeting its primary endpoint in the Miranda trial in patients with chronic obstructive pulmonary disease. The Cambridge, England-based pharmaceutical company said that in the ‘pivotal’ trial, the monoclonal antibody demonstrated a statistically significant and meaningful reduction in the annualised rate of moderate-severe COPD exacerbations in the primary population of former smokers, along with the overall population. AstraZeneca noted this included both former and current smokers, as well as patients across all blood eosinophil counts and all stages of lung function severity. Almost 400 million people globally are diagnosed with COPD every year, said AstraZeneca, noting that it is the third leading cause of death globally. AstraZeneca said the results follow on from the positive results from the phase three Oberon and Titania trials assessing Tozorakimab at a four-week dosing interval. Shares in AstraZeneca fell 1.0% to 14,974.10 pence on Monday morning in London. ‘These data further demonstrate tozorakimab’s exciting potential as a first-in-class biologic with a truly differentiated mechanism of action that inhibits the signalling of the reduced and oxidised forms of IL-33 to address underlying drivers of COPD. We look forward to sharing the data with regulators and the scientific community as soon as possible,’ said Sharon Barr, executive vice president, BioPharmaceuticals R&D at AstraZeneca. Copyright 2026 Alliance News Ltd. All Rights Reserved.
|
